Literature DB >> 1911144

Angiotensin converting enzyme inhibitors for reduction of proteinuria in children with steroid-resistant nephrotic syndrome.

D S Milliner1, B Z Morgenstern.   

Abstract

The effects of angiotensin converting enzyme inhibitors (ACEI) on proteinuria, renal function, and serum proteins were evaluated in six children with steroid-resistant nephrotic syndrome and proteinuria of 3-15 g/24 h (277 +/- 47 mg/m2 per hour). Following ACEI, proteinuria decreased from 7,408 +/- 2,385 (mean +/- SEM) to 3,746 +/- 1,395 mg/24 h (P less than 0.05). Creatinine clearance was 87.8 +/- 22.6 before and 96.4 +/- 23.6 ml/min per 1.73 m2 after ACEI. In two patients, inulin and para-aminohippuric acid clearances were normal before and after ACEI, together with parallel reductions of urine protein of 50% and 46%. Clearance of total protein was reduced by 56% following ACEI, compared with reduction in the clearance of gamma globulin by 58% and albumin by 39.5%. No significant change was seen in blood pressure, serum albumin, or total protein following ACEI. After ACEI, diuretic doses were able to be reduced or eliminated in three patients. Reduction of proteinuria was sustained during a followup period of 11-20 months in three patients. ACEI may be of benefit in the clinical management of children with steroid-resistant nephrotic syndromes, allowing reduction in diuretic requirements.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1911144     DOI: 10.1007/bf00856646

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  30 in total

1.  In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system.

Authors:  J R Ingelfinger; W M Zuo; E A Fon; K E Ellison; V J Dzau
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

2.  Extrarenal complications of the nephrotic syndrome.

Authors:  D B Bernard
Journal:  Kidney Int       Date:  1988-06       Impact factor: 10.612

3.  Captopril and proteinuria in diabetes mellitus.

Authors:  E S Kisch
Journal:  Isr J Med Sci       Date:  1987-07

Review 4.  The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.

Authors:  T H Hostetter; H G Rennke; B M Brenner
Journal:  Am J Med       Date:  1982-03       Impact factor: 4.965

5.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension.

Authors:  R Zatz; B R Dunn; T W Meyer; S Anderson; H G Rennke; B M Brenner
Journal:  J Clin Invest       Date:  1986-06       Impact factor: 14.808

6.  Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome.

Authors:  S Anderson; J R Diamond; M J Karnovsky; B M Brenner
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

7.  Efficacy and renal effects of enalapril therapy for hypertensive patients with chronic renal insufficiency.

Authors:  P A Abraham; J A Opsahl; C E Halstenson; W F Keane
Journal:  Arch Intern Med       Date:  1988-11

8.  Angiotensin II directly stimulates sodium transport in rabbit proximal convoluted tubules.

Authors:  V L Schuster; J P Kokko; H R Jacobson
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

9.  Angiotensin II: a potent regulator of acidification in the rat early proximal convoluted tubule.

Authors:  F Y Liu; M G Cogan
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

10.  Role for angiotensin II in an overt functional proteinuria.

Authors:  T Yoshioka; T Mitarai; V Kon; W M Deen; H G Rennke; I Ichikawa
Journal:  Kidney Int       Date:  1986-10       Impact factor: 10.612

View more
  15 in total

1.  Increasing frequency of acute kidney injury amongst children hospitalized with nephrotic syndrome.

Authors:  Michelle N Rheault; Chang-Ching Wei; David S Hains; Wei Wang; Bryce A Kerlin; William E Smoyer
Journal:  Pediatr Nephrol       Date:  2013-09-14       Impact factor: 3.714

Review 2.  Is there any reason to lower proteinuria in a child with nephrotic-range proteinuria who is not clinically edematous?

Authors:  D Kees-Folts
Journal:  Pediatr Nephrol       Date:  1996-04       Impact factor: 3.714

3.  Management of congenital nephrotic syndrome.

Authors:  Larisa Kovacevic; Christopher J D Reid; Susan P A Rigden
Journal:  Pediatr Nephrol       Date:  2003-04-08       Impact factor: 3.714

4.  Effect of fosinopril in children with steroid-resistant idiopathic nephrotic syndrome.

Authors:  Zhuwen Yi; Zhihui Li; Xiao-Chuan Wu; Qing-Nan He; Xi-Qiang Dang; Xiao-Jie He
Journal:  Pediatr Nephrol       Date:  2006-05-06       Impact factor: 3.714

5.  Long-term therapy with enalapril in patients with nephrotic-range proteinuria.

Authors:  W Proesmans; I V Wambeke; M V Dyck
Journal:  Pediatr Nephrol       Date:  1996-10       Impact factor: 3.714

6.  Angiotensin converting enzyme inhibitor does not reduce proteinuria in an infant with congenital nephrotic syndrome of the Finnish type.

Authors:  R Birnbacher; E Förster; C Aufricht
Journal:  Pediatr Nephrol       Date:  1995-06       Impact factor: 3.714

7.  Progression of chronic renal failure in children with dysplastic kidneys.

Authors:  Claudia González Celedón; María Bitsori; Kjell Tullus
Journal:  Pediatr Nephrol       Date:  2007-03-23       Impact factor: 3.714

Review 8.  Treatment strategies in patients with chronic renal disease: ACE inhibitors, angiotensin receptor antagonists, or both?

Authors:  Karl F Hilgers; Jörg Dötsch; Wolfgang Rascher; Johannes F E Mann
Journal:  Pediatr Nephrol       Date:  2004-07-22       Impact factor: 3.714

9.  Antiproteinuric effects of enalapril and losartan: a pilot study.

Authors:  Colin Thomas White; Catherine Fiona Macpherson; Robert Morrison Hurley; Douglas George Matsell
Journal:  Pediatr Nephrol       Date:  2003-08-12       Impact factor: 3.714

10.  Enalapril dosage in steroid-resistant nephrotic syndrome.

Authors:  Arvind Bagga; Basanagoud D Mudigoudar; Pankaj Hari; Vandita Vasudev
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.